Cardiofaciocutaneous syndrome

O que é Cardiofaciocutaneous syndrome?

Cardiofaciocutaneous syndromeé uma doença genética rara que se apresenta com características faciais muito distintas e uma ampla gama de condições de saúde que afetam a pele e o cabelo dos indivíduos afetados. Os defeitos cardíacos também são comuns com o síndromes.

Pertence ao grupo de doenças RASopatias que se distinguem por suas causas e características genéticas. Outro síndromes dentro deste grupo incluem Costello e Noonan síndromes.

Quais mudanças genéticas causam Cardiofaciocutaneous syndrome?

A síndromes ocorre devido a mutações nos seguintes genes: BRAF, MAP2K1 (MEK1), MAP2K2 (MEK2), KRAS. Acredita-se que as mutações sejam principalmente espontâneas e não hereditárias.

Em alguns casos, uma síndrome genética pode ser o resultado de uma mutação de novo e o primeiro caso em uma família. Neste caso, trata-se de uma nova mutação gênica que ocorre durante o processo reprodutivo.

Quais são os principais sintomas de Cardiofaciocutaneous syndrome?

Os principais sintomas da síndromes são atraso global de desenvolvimento e deficiência intelectual.

Problemas de alimentação também são comuns, o que, por sua vez, provoca uma falha de crescimento.

Os defeitos cardíacos congênitos são outro sintoma comum da síndrome. Os defeitos cardíacos específicos associados à síndrome podem incluir estenose pulmonar, defeito do septo atrial e cardiomiopatia hipertrófica.

Problemas com os olhos, visão e visão também são comuns.

As características físicas da síndrome incluem uma testa proeminente, um estreitamento anormal de ambos os lados da testa, um nariz curto e pouca ou nenhuma sobrancelha e cílios.

Os indivíduos com a síndrome também são caracterizados por seus cabelos ralos, quebradiços e cacheados. Muitos indivíduos sofrem de doenças de pele que variam de pele seca a hiperqueratose mais grave.

Como alguém faz o teste de Cardiofaciocutaneous syndrome?

O teste inicial para a síndromes cardiofaciocutânea pode começar com a triagem de análise facial, por meio da plataforma de telegenética da FDNA Telehealth, que pode identificar os principais marcadores da síndrome e apontar a necessidade de novos testes. Seguirá uma consulta com um conselheiro genético e, em seguida, um geneticista. 

Com base nesta consulta clínica com um geneticista, as diferentes opções para testes genéticos serão compartilhadas e o consentimento será solicitado para testes adicionais.

Informações médicas sobre Cardiofaciocutaneous syndrome

Cardio-facio-cutaneous syndrome has many features in common with Noonan syndrome, but it is a separate entity. The cardiac features are variable, but a pulmonary stenosis is the most common, next being an ASD. The facial features are similar to Noonan syndrome, but the hair is especially sparse, friable and curly. The head is relatively big when compared with height and there is a noticeable bi-temporal constriction. The skin is dry, and hyperkeratotic lesions develop, especially over the extensor surfaces. There might be true ichthyosis. The condition was named by Reynolds et al., (1986). Baraitser and Patton (1986) probably described the same condition. Costello et al., (1977) (qv) described similar cases with nasal papillomata. This is a separate condition.
Ades et al., (1992) reported a case with segmental optic nerve dysplasia and poor development of papillomacular bundles. Young et al., (1993) reviewed the ophthalmological findings in three cases, and the cases from the literature. They found strabismus and ptosis in about 50% and nystagmus in 30%. Dunya et al., (1993) reported a case with a retinal dystrophy. Lorenzetti and Fryns (1996) reported a possible case with overlapping features of Noonan syndrome who had retinitis pigmentosa. Kiss and Torok (1992) reported two likely cases under the designation of Salamon syndrome. No heart defects were mentioned but the other features were characteristic for CFC syndrome. Fryns et al., (1992) and Ward et al., (1994) reported possible dominant families, however, the affected individuals did not have as severe manifestations as some other cases in the literature and these families may suggest further evidence of a 'Noonan-CFC spectrum'. Leichtman (1996) reported a 4 1/2-year-old girl with convincing features of the condition whose mother had classical Noonan syndrome. McDaniel and Fujimoto (1997) reported a case with intestinal malrotation. van den Berg and Hennekam (1999) report a five-year-old girl with features of the condition who developed acute lymphoblastic leukaemia. Two further cases with overlapping features of Noonan and CFC syndromes were reported by Krajewska-Walasek (1996). Manoukian et al., (1996) reported a 25-year-old female with some features of the condition who had normal intelligence. However, she could have had simple Noonan syndrome. The mother and daughter reported by Lecora et al., (1996) may well have had NF1 with features of Noonan syndrome. Sabatino et al., (1997) reported a follow up of two cases revealing significant developmental delay. Legius et al., (1998) reported a family where some cases had features of CFC syndrome (although relatively mildly). The gene mapped to the Noonan region.
Grebe and Clericuzio (2000) reported two patients with features of the condition, and outlined diagnostic criteria. Kavamura et al., (2002) report a CFC index for the diagnosis of the condition. However, application of this index appears to be very time consuming and its validity as a diagnostic tool appears to be unsubstantiated. Ion et al., (2002) could find no evidence of PTPN11 mutations in 28 cases of CFC and neither could Kavamura, in 10 cases or Musante et al., (2003) in five cases, or Troger et al., (2003) in 18 cases of CFC syndrome. Schollen et al., (2003) reported a large family segregating for Noonan syndrome previously reported by Legius et al., (1998) and Fryns et al., (1992). Two brothers in the family are said to have a phenotype suggestive of CFC syndrome with mild mental retardation, dry scaly skin and sparse scalp hair. Rauen et al., (2000) reported an 18-month-old girl, apparently with features of the condition, who had 12q21.2->q22 deletion, not thought to encompass the Noonan syndrome locus. Unfortunately, clinical photographs were not published. The further case with a 12q21.2-q22 deletion reported by Rauen et al., (2002) as having features of CFC syndrome, is somewhat unconvincing. See also comments by Neri et al., (2003) and James et al., (2005). Ishiguro et al., (2002) reported a case associated with moyamoya syndrome. Chan et al., (2002) reported a case with a spontaneous chylothorax. Some cases have rather a coarse facial appearance, and as an enlarged liver and spleen have been found many patients have been investigated for a storage disorder, but nothing has been detected. Most cases have been isolated. Leukaemia might be an occasional manifestation (Makita et al., 2007). An excellent AD family with a MEK2 mutation was reported by Linden and Price (2011). McGaughran et al., (2003) reported a 52-year-old woman with features of the condition. Additional features (islet cell hyperplasia, lymphoid depletion, thymus atrophy and a peripheral neuropathy with onion bulbs) were reported by Manci et al., (2005). The condition has now been mapped, and mutations found in KRAS and BRAF. (Niihori et al., 2006). These are key regulators of the RAS-RAF-MEK-ERK pathway, which is important for proliferation, growth and death of cells. Niihori et al., (2006) found that those with BRAF mutations had the classical skin changes, but not those with KRAS mutations. The latter could easily be mistaken for Noonan or Costello syndrome - see elsewhere. Rauen (2006), reported three patients, thought to have Costello syndrome (there were no cardiac lesions and they were HRAS negative), who turned out to have CFC with BRAF mutations (in two). She points out the usefulness of mutation analysis in distinguishing the two conditions. In a series of patients with a KRAS mutation, the clinical phenotype ranged from Noonan, to CFC and even Costello syndrome (Zenker et al., 2007). One of the Costello patients had a Dandy-Walker malformation and although all the CFC patients with KRAS mutations had sparse hair, none had hyperkeratosis or ichthyosis. Tang et al., (2007) reported a patient with a KRAS mutation and an ulcerating hemangioma. The overlap of CFC with Costello was emphasised by Narumi et al., (2007). Between 30-40% of patients with the CFC mutation (BRAF, MAP2K1/2) had wrinkled palms and soles, hyperpigmentation and joint hyperextension, features thought common to Costello syndrome. Nava et al., (2007) suggest, that unlike Costello where patients should have an HRAS mutation, those with BRAF, KRAS, MEK1 and two mutations should be accorded the diagnosis of CFC or Noonan syndrome dependent on the phenotype. SOS1 mutations (see Noonan syndrome) can also cause this phenotype (Narumi et al., 2008).
Note that some patients might early-on be thought to have mitochondrial disease (Kleefstra et al., 2011). A peripheral neuropathy in a mother and son with KRAS mutations was reported by Stark et al., (2012). Four patients were reported by Wright et al., (2011) with 17q21.31 microdeletions who had skin hyperpigmentation, numerous nevi and coarse facial features. Wright et al., (2011), suggest that this microdeletion should be in the differential diagnosis of CFC.
Note the four-generation family with a MEK2 mutation reported by Rauen et al., (2010) and the father and son with mild phenotype (Karaer et al., 2015).
Kimiko et al. (2017) reported patients with craniosynostosis and Noonan syndrome (mutations in PTPN11) and CFC syndrome (mutations in BRAF or KRAS).
Two siblings with heterozygous BRAF c.770A> G (p.Gln257Arg) mutation were reported by Geoghegan et al., (2018). The mutation was not found in parental leukocyte DNA and it was presumed to be a case of gonadal mosaicism.
Bessis et al. (2018) summarized dermatological findings in 45 mutation-positive individuals. Hair abnormalities included scarce/absent eyebrows in 73% and wavy or curly hair in 69%. Skin findings were keratosis pilaris (82%), ulerythema ophryogenes (44%), multiple melanocytic naevi (29%) and palmo-plantar hyperkeratosis (27%). Oral acitretin was beneficial for management of palmo-plantar hyperkeratosis, whereas treatment of ulerythema ophryogenes by topical 1% sirolimus was unsuccessful.

* This information is courtesy of the L M D.
If you find a mistake or would like to contribute additional information, please email us at: [email protected]

Seja mais rápido e preciso Diagnóstico Genético!

Mais de 250,000 pacientes analisados com sucesso!
Não espere anos por um diagnóstico. Aja agora e economize um tempo valioso.

Começa aqui!

"Nosso caminho para o diagnóstico de uma doença rara foi uma jornada de 5 anos que só posso descrever como uma viagem sem mapa. Não sabíamos nosso ponto de partida. Não sabíamos nosso destino. Agora nós temos esperança. "

Imagem

Paula e Bobby
Pais de lillie

O que é FDNA Telehealth?

A FDNA Telehealth é uma empresa líder em saúde digital que fornece acesso mais rápido a análises genéticas precisas.

Com uma tecnologia hospitalar recomendada pelos principais geneticistas, nossa plataforma exclusiva conecta pacientes a Especialistas Em Genética para responder às suas perguntas mais urgentes e esclarecer quaisquer dúvidas que possam ter sobre seus Sintomas.

Benefícios do FDNA Telehealth

Ícone FDNA

Credibility

Nossa plataforma é usada atualmente por mais de 70% dos geneticistas e tem sido usada para diagnosticar mais de 250,000 pacientes em todo o mundo.

Ícone FDNA

Acessibilidade

O FDNA Telehealth fornece análise facial e triagem em minutos, seguido por acesso rápido a conselheiros genéticos e geneticistas.

Ícone FDNA

Fácil de usar

Nosso processo contínuo começa com um diagnóstico online inicial por um conselheiro genético e segue por consultas com geneticistas e testes genéticos.

Ícone FDNA

Acurácia - Precisão

Recursos e tecnologia avançada de inteligência artificial (AI) com uma taxa de precisão de 90% para uma maior precisão análise genética.

Ícone FDNA

Valor para
Dinheiro

Acesso mais rápido a conselheiros genéticos, geneticistas, testes genéticos e um diagnóstico. Em até 24 horas, se necessário. Economize tempo e dinheiro.

Ícone FDNA

Privacidade e segurança

Garantimos a máxima proteção de todas as imagens e informações do paciente. Seus dados estão sempre protegidos, protegidos e criptografados.

O FDNA Telehealth pode aproximar você de um diagnóstico.
Agende uma reunião de Aconselhamento Genitico online dentro de 72 horas!

EspañolDeutschPortuguêsFrançaisEnglish